Journal article
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
- Abstract:
-
Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review the acquired mutations in the tyrosine kinase encoded by the BCR-ABL1 gene underlying Glivec failure or resistance in a cohort of 388 imatinib-treated CML patients (149 Female and 239 male) regist...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Novartis
More from this funder
Max Foundation
More from this funder
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- British Journal of Haematology Journal website
- Volume:
- 177
- Issue:
- 6
- Pages:
- 1000–1007
- Publication date:
- 2017-05-01
- Acceptance date:
- 2017-03-20
- DOI:
- ISSN:
-
1365-2141
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:693474
- UUID:
-
uuid:0ae57794-700f-46e1-b5bf-f2b220d64680
- Local pid:
- pubs:693474
- Source identifiers:
-
693474
- Deposit date:
- 2017-05-17
Terms of use
- Copyright date:
- 2017
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record